Overview

A Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 5-part study. The study duration will be approximately 60 days for Part A and approximately 90 days for Parts B, C, D, and E.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company